Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 3 of 15
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
AdventHealth
NCT07231159
Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment
Ryan J. Halter
NCT06039085
Ablative Therapy in the Management of Prostate Cancer
Weill Medical College of Cornell University
NCT03492424
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
NCT06150417
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Jonsson Comprehensive Cancer Center
NCT07293585
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Weill Medical College of Cornell University
NCT05948657
Prostate Tissue BioBank
Abramson Cancer Center at Penn Medicine
NCT06659614
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
Albany Medical College
NCT05629494
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Icahn School of Medicine at Mount Sinai
NCT06945315
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Columbia University
NCT05351424
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
NCT01492972
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Hoag Memorial Hospital Presbyterian
NCT04700332
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
University of Chicago
NCT05710380
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
M.D. Anderson Cancer Center
NCT06785441
CV CARE: CardioVascular Care in PC Patients
Dana-Farber Cancer Institute
NCT06202820
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Global Development
NCT04729114
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
Linda Chan, MD
NCT04552509
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
Robert Bok, MD, PhD
NCT06391034
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
University of Chicago
NCT06824818
SBRT Boost for Unfavorable Prostate Cancer'
MemorialCare Health System
NCT02016248
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
University of California, Davis
NCT06101290
Investigation of Impact of AI on Prostate Cancer Workflow
Case Comprehensive Cancer Center
NCT07084779
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics
NCT06511141
Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
University of California, San Diego
NCT06990542
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Columbia University
NCT06226129
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
University of Oklahoma
NCT06960798
Serial MRI Scans During Radiation Therapy
Dana-Farber Cancer Institute
NCT04188535
Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
University of Miami
NCT02997709
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Cedars-Sinai Medical Center
NCT06437574
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
University of Michigan Rogel Cancer Center
NCT05038332
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
NCT07001241
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Varian, a Siemens Healthineers Company
NCT05804318
Effect of Text Message Reminders on M-ISI Score After Prostate Surgery
University of Rochester
NCT07071207
The University of Miami Adapt (UAdapt) Trial
University of Miami
NCT06111313
A Study of Mental Health Care in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT06037954
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Martha Mims
NCT03833921
Mechanisms of Resistance to PSMA Radioligand Therapy
University of California, San Francisco
NCT05435495
TERPS Trial for de Novo Oligometastic Prostate Cancer
University of Maryland, Baltimore
NCT05223803
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT04503265
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
NCT06274047
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
AstraZeneca
NCT05938270
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Duke University
NCT06141993
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Icahn School of Medicine at Mount Sinai
NCT07285057
Geriatric Assessment and Technology Evaluation in Prostate Cancer
University of Chicago
NCT06215508
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
MidLantic Urology
NCT05799248
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
NCT04903873
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
NCT05765500
HIFU for Focal Ablation of Prostate Tissue: An Observational Study
University of California, Los Angeles
NCT03620786
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.